About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Logout
Obstetrics and Gynegology2020№5
The endometrium as a target...

The endometrium as a target organ in postmenopausal women

DOI
https://dx.doi.org/10.18565/aig.2020.5.166-72

Andreeva E.N., Sheremetyeva E.V., Grigoryan O.R., Mikheev R.K., Absatarova R.K.

1) National Medical Research Center of Endocrinology, Ministry of Health of Russia, Moscow, Russia; 2) Department of Reproductive Medicine and Surgery, Faculty of Advanced Professional Education, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia; 3) A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
Postmenopausal women are at risk for different endometrial abnormalities in the presence of involutional changes in the reproductive system and features of the somatic status. 40-60% of women receiving low-dose and microdose menopausal hormone therapy may notice vaginal bleeding of various intensities, which is not organic and, on the one hand, results in discontinuation of therapy and a reduction in its adherence, and, on the other, in psychological impairment. The literature review presents data from randomized controlled studies analyzing the minimally effective and safe dose of menopausal hormone therapy and its impact on the endometrium. Literature was searched for in Russian (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The priority was free access to the full-text articles published in 2014 to 2020.

Keywords

postmenopause
menopausal hormone therapy
endometrium
drospirenone
estrogens
Full text (in Russian)

References

  1. Адамян Л.В., Мельникова Н.С., Зайратьянц О.В., Балицкий Е.В., Кортукова Р.А., Козлова О.В. Патология эндометрия в пожилом и старческом возрасте (скрининговое исследование). Архив патологии. 2013; 75(6): 32-8. [Adamyan L.V., Melnikova N.S., Zairatyants O.V., Balitsky E.V., Kortukova R.A., Kozlova O.V. Pathology of the endometrium in the elderly and senile age (screening study). Archive of Pathology. 2013; 75(6): 32-8.(in Russian)].
  2. Globocan 2012. Cancer Incidence and Mortality Worldwide: IARC Cancer Base № 11. Lyon, France: IARC; 2013. Accessed January 30, 2018. Available at: http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012
  3. Аксель Е.М. Заболеваемость и смертность от злокачественных новообразований органов женской репродуктивной системы в России. Онкогинекология. 2015; 1: 4-13. [Aksel E.M. Morbidity and mortality from malignant neoplasms of the female reproductive system in Russia. Oncogynecologia. 2015; (1): 4-13. (in Russian).]
  4. Адамян Л.В., Мельникова Н.С., Касян В.Н. Патология эндометрия в постменопаузе: нужен ли ультразвуковой скрининг? Проблемы репродукции. 2019; 25(2): 113-9. https://dx.doi.org/10.17116/repro201925021113. [Adamyan L.V., Melnikova N.S., Kasyan V.N. Endometrial pathology in postmenopausal women: is ultrasound screening needed? Reproduction Problems. 2019; 25(2): 113-9. (in Russian)].
  5. Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., Sessa C.; ESMO Guidelines Working Group. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(6): 33-8. https://dx.doi.org/10.1093/annonc/mdt353.
  6. Lortet-Tieulent J., Ferlay J., Bray F., Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J. Natl. Cancer Inst. 2018; 110(4): 354-61. https://dx.doi.org/10.1093/jnci/djx214.
  7. Гасанова С.Х. Низкодозированная гормонотерапия в постменопаузе – состояние эндометрия и маточного кровотока: автореф. дисc. ... канд. мед. наук. М.; 2007. 26 с. [Hasanova S.Kh. Low-dose hormone therapy in postmenopausal women - the state of the endometrium and uterine blood flow. Diss. Moscow; 2007. 26 p.(in Russian)].
  8. Gompel A. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. Review. Climacteric. 2018; 21(4): 321-5.
  9. Pal N., Broaddus R.R., Urbauer D.L., Balakrishnan N., Milbourne A., Schmeler А. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet. Gynecol. 2018; 131: 109-16.
  10. Макаров О.В., Сергеев П.В., Карева Е.Н. Гиперпластические процессы эндометрия: диагностика и лечение с учетом рецепторного профиля эндометрия. Акушерство и гинекология. 2003; 3: 32-6. [Makarov O.V., Sergeev P.V., Kareva E.N. Endometrial hyperplastic processes: diagnosis and treatment according to receptor profile of endometrium. Akusherstvo i ginekologiya. 2003; (3): 32-6. (in Russian)].
  11. Shanthala S., Subramanya H. Immunohistochemical study of hormonal receptors in endometrium of women with dysfunctional uterine bleeding: a two year experience of a tertiary care center. Arch. Med. 2018; 10(6). https://dx.doi.org/10.21767/1989-5216.1000289.
  12. Bircan S., Ensari A., Ozturk S., Erdogan N., Dundar I., Ortac F. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol. Oncol. Res. 2005; 11(1): 32-9.
  13. Hu K., Zhong G., He F. Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int. J. Gynecol. Cancer. 2005; 15(3): 537-41.
  14. Hapangama D., Kamal A., Bulmer J. Estrogen receptor β: the guardian of the endometrium. Hum. Reprod. Update. 2014; 21(2): 174-93. https://dx.doi.org/10.1093/humupd/dmu053.
  15. Бреусенко В.Г., Карева Е.Н., Голухов Г.Н., Ивановская Т.Н., Голова Ю.А., Коцюбинская Н.А., Бехбудова Л.Х., Степанов К.И., Воробьева Г.Ю. Пролиферативные процессы в эндометрии у пациенток в пре- и постменопаузе. Влияние патологической пролиферации на стероидно-рецепторный профиль эндометрия. Российский вестник акушера-гинеколога. 2016; 16(4): 25-31. https://dx.doi.org/10.17116/rosakush201616425-31. [Breusenko V.G., Kareva E.N., Golukhov G.N., Ivanovskaya T.N., Golov Yu.A., Kotsyubinskaya N.A., Bekhbudova L.Kh., Stepanov K.I., Vorobyova G.Yu. Proliferative processes in the endometrium in patients in pre- and postmenopausal women. The effect of pathological proliferation on the steroid-receptor profile of the endometrium. Russian Bulletin of the Obstetrician-Gynecologist. 2016; 16(4): 25-31. https://dx.doi.org/10.17116/rosakush201616425-31. (in Russian)].
  16. Teresiński L., Sipak O., Rył A., Masiuk M., Rotter I., Ratajczak W.et al. Assessment of morphological changes and steroid receptors in the uteri of postmenopausal women. Histol. Histopathol. 2019; 34(6): 631-44. https://dx.doi.org/10.14670/HH-18-063.
  17. Carugno J. Clinical management of vaginal bleeding in postmenopausal women 2020. Climacteric. 2020; Apr 1: 1-7. https://dx.doi.org/10.1080/13697137.2020.1739642.
  18. Begum J., Samal R. A clinicopathological evaluation of postmenopausal bleeding and its correlation with risk factors for developing endometrial hyperplasia and cancer: A Hospital-Based Prospective Study. J. Midlife Health. 2019; 10(4): 179-83. https://dx.doi.org/10.4103/jmh.JMH_136_18.
  19. Burbos N., Musonda P., Duncan T.J., Crocker S.G., Nieto J.J., Morris E.P. Postmenopausal vaginal bleeding in women using hormone replacement therapy. Menopause Int. 2012; 18: 5-9.
  20. Clarke M.A., Long B.J., Sherman M.E., Lemens M.A., Podratz K.C., Hopkins M.R. et al. A prospective clinical cohort study of women at increased risk for endometrial cancer. Gynecol. Oncol. 2020; 156(1): 169-77. https://dx.doi.org/10.1016/j.ygyno.2019.09.014.
  21. Ghoubara A., Sundar S., Ewies A.A. Predictors of malignancy in endometrial polyps: study of 421 women with postmenopausal bleeding. Climacteric. 2018; 21: 82-7.
  22. Lee S.C., Kaunitz A.M., Sanchez-Ramos L., Rhatigan R.M. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet. Gynecol. 2010; 116: 1197-205.
  23. Trabert B., Wentzensen N., Yang H.P., Sherman M.E., Hollenbeck A.R., Park Y., Brinton L.A. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int. J. Cancer. 2013; 132(2): 417-26. https://dx.doi.org/10.1002/ijc.27623.
  24. Hein A., Schneider M.O., Renner S.K., Fasching P.A., Fiessler C., Titz S. et al. Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. Arch. Gynecol. Obstet. 2020; 301(1): 289-94. https://dx.doi.org/10.1007/s00404-019-05414-3.
  25. Di Donato V., Palaia I., D’Aniello D., Musacchio L., Santangelo G., Di Mauro F. et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review. Oncology. 2020; 98(4): 195-201. https://dx.doi.org/10.1159/000505427.
  26. Rotenberg O., Fridman D., Doulaveris G., Renz M., Kaplan J., Gebb J. et al. Long-term outcome of postmenopausal women with non-atypical endometrial hyperplasia on endometrial sampling. Ultrasound Obstet. Gynecol. 2020; 55(4): 546-51. https://dx.doi.org/10.1002/uog.20421.
  27. Luo J., Hendryx M., Manson J.E., Figueiredo J.C., LeBlanc E.S., Barrington W. et al. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 2019; 3(4): pkz054. https://dx.doi.org/10.1093/jncics/pkz054.
  28. Lega I.C., Lipscombe L.L. Review: Diabetes, obesity, and cancer-pathophysiology and clinical implications. Endocr. Rev. 2020; 41(1). pii: bnz014. https://dx.doi.org/10.1210/endrev/bnz014.
  29. Walsh D.M., Hokenstad A.N., Chen J., Sung J., Jenkins G.D., Chia N. et al. Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). Sci. Rep. 2019; 9(1): 19213. https://dx.doi.org/10.1038/s41598-019-55720-8.
  30. Sturdee D.W., Pines A.; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14: 302-20. https://dx.doi.org/10.3109/13697137.2011.570590.
  31. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012; 19: 257-71. https://dx.doi.org/10.1097/gme.0b013e31824b970a.
  32. Gerlinger C., Gude K., Schmelter T., Schaefers M., Endrikat J. 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric. 2015; 18(4): 512-7. https://dx.doi.org/10.3109/13697137.2015.1036855.
  33. Archer D.F., Thorneycroft I.H., Foegh M. et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005; 12: 716-27. https://dx.doi.org/10.1097/01.gme.0000177318.24005.b1.
  34. Григорян О.Р. Эффективность и безопасность использования ультранизких доз дроспиренона и 17β-эстрадиола у женщин в постменопаузе. Мета-анализ. Медицинский cовет. 2018; 7: 126-32. https://dx.doi.org/10.21518/2079-701X-2018-7-126-132. [Grigoryan O.R. Efficacy and safety of the use of ultra-low doses of drospirenone and 17β-estradiol in postmenopausal women. Meta-analysis. Medical Advice. 2018; (7): 126-32. https://dx.doi.org/10.21518/2079-701X-2018-7-126-132.(in Russian)].
  35. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005; 8: 4-12. https://dx.doi.org/10.1080/13697130500330382.
  36. Mueck A.O., Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2005; 3: 45-54. https://dx.doi.org/10.2174/1568016052773270.
  37. Genazzani A.R., Schmelter T., Schaefers M., Gerlinger C., Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β -estradiol in postmenopausal women. Climacteric. 2013; 16: 490-8. https://dx.doi.org/10.3109/13697137.2013.783797.
  38. Gerlinger C., Gude K., Alincic-Kunz S., Schafers M. Recommendation for the collection and analysis of endometrial biopsies for hormone therapies. Climacteric. 2012; 15: 52-8. https://dx.doi.org/10.3109/13697137.2011.587055.
  39. Kurman R.J., Hedrick Ellenson L., Ronnett B.M. Blaustein’s pathology of the female genital tract. 6th ed. New York: Springer; 2011. https://dx.doi.org/10.1007/978-3-319-46334-6.
  40. Hunter M.S. The Women’s Health Questionnaire: a measure of mid-aged women’s perceptions of their emotional and physical health. Psychol. Health. 1992; 7: 45-54. https://dx.doi.org/10.1186/1477-7525-1-41.

Received 15.05.2020

Accepted 20.05.2020

About the Authors

Elena N. Andreeva, MD, professor of the cathedra of Reproductive medicine and Surgery of A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Russian Ministry of Health, the Leader of the Endocrinological Gynecology Department of the Endocrinology Research Centre of the Russian Ministry of Health.
Tel.: +7(495)500-00-90, +7(495)609-67-00. E-mail: endogin@mail.ru. ORCID: 0000-0001-8425-0020.
11 Dm. Ulyanov str., Moscow, 117036, Russian Federation; 20/1 Delegatskaya Str., Moscow, 127473, Russian Federation.
Olga R. Grigoryan, MD, Professor, main research worker of the Endocrinological Gynecology Department of the Endocrinology Research Centre of the Russian Ministry
of Health. Tel.: +7(495)500-00-90. E-mail: iceberg1995@mail.ru. ORCID: 0000-0003-4979-7420. 11 Dm. Ulyanov str., Moscow, 117036, Russian Federation.
Robert K. Mikheev, medical student of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Russian Ministry of Health. Tel.: +7(495)609-67-00.
E-mail: iceberg1995@mail.ru. ORCID: 0000-0001-5826-3186. 20/1 Delegatskaya str., Moscow, 127473, Russian Federation.
Ekaterina V. Sheremetyeva, MD, PhD, lead employee of the Endocrinological Gynecology Department of the Endocrinology Research Centre of the Russian Ministry
of Health. Tel.: +7(495)500-00-90. E-mail: s1981k@yandex.ru. ORCID: 0000-0001-7177-0254. 11 Dm. Ulyanov str., Moscow, 117036, Russian Federation.
Yulia S. Absatarova, MD, PhD, researcher of the Endocrinological Gynecology Department of the Endocrinology Research Centre of the Russian Ministry of Health.
Tel.: +7(495)500-00-90. E-mail: korsil2008@ya.ru. ORCID: 0000-0003-0696-5367. 11 Dm. Ulyanov str., Moscow, 117036, Russian Federation.

For reference: Andreeva E.N., Sheremetyeva E.V., Grigoryan O.R., Mikheev R.K., Absatarova R.K. The endometrium as a target organ in postmenopausal women.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 5: 166-72(In Russian).
https://dx.doi.org/10.18565/aig.2020.5.166-72

Similar Articles

№8 / 2023
Ermakova E.I., Smetnik A.A.
Experience in the clinical use of a non-hormonal vaginal cream for the treatment of genitourinary syndrome of menopause/vulvovaginal atrophy in patients with a history of estrogen-dependent oncological diseases
№4 / 2023
Averyanova M.V., Yureneva S.V., Kiseleva V.V., Yakushevskaya O.V., Iskusnykh M.E., Elchaninov A.V., Fatkhudinov T.Kh., Vishnyakova P.A.
Impact of menopausal hormone therapy on immune system parameters
№4 / 2023
Babaeva N.А., Yureneva S.V., Aleshikova О.I., Yakushevskaya О.V., Ashrafyan L.A.
Impact of hormone therapy on the overall and relapse‑free survival of patients receiving treatment for ovarian cancer
№6 / 2024
Yashchuk A.G., Dautova L.A., Shaikhutdinova O.V., Muslimova L.R., Berg P.A., Berg E.A., Nasyrova S.F., Kizko I.A., Nazyrova A.G.
Possibilities of the biologically active complex of phytopreparations in the correction of menopausal disorders
№5 / 2024
Ramazanova М.О., Apolikhina I.A., Shershakova E.I.
Modern problems and opportunities in the treatment of genitourinary syndrome of menopause in the context of medical science and technology development
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.